Valantine Hannah's Form 4/A amendment
AmendedBridgeBio Pharma, Inc. (BBIO) · filed Jun 30, 2025
- Accession no.
- 0000950170-25-091756
- Filed
- Jun 30, 2025
- Trade date
- Dec 28, 2021
- Filing delay
- 1,280 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 13, 2024
This filing lists 2 non-derivative transactions. Open-market purchases total $30.0K. It was filed 1,280 days after the trade.
This amendment replaces 0000950170-24-014523 (filed Feb 13, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valantine HannahCIK 0001855608 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +1,542 | $12.68 | +$19,552.56 | 1,542 | Direct | |
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +796 | $13.16 | +$10,475.36 | 2,687 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
This amendment has no footnotes.